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Objectives
We evaluated the emergence of drug resistance in patients failing first-line regimens containing
one nonnucleoside reverse transcriptase inhibitor (NNRTI) administered with zidovudine (ZDV) +
lamivudine (the ZDV group) or non-thymidine analogues (non-TAs) (tenofovir or abacavir,
+ lamivudine or emtricitabine; the non-TA group).
Methods
Three hundred HIV-1-infected patients failing a first-line NNRTI-containing regimen (nevirapine,
n = 148; efavirenz, n = 152) were included in the analysis. Virological failure was defined as
viraemia  400 HIV-1 RNA copies/mL for the first time at least 6 months after starting the
NNRTI-based regimen. For each patient, a genotypic resistance test at failure was available.
The presence of drug-resistance mutations in HIV-1 reverse transcriptase was evaluated by
comparing patients treated with NNRTI + zidovudine + lamivudine vs. those treated with
NNRTI + non-TA.
Results
A total of 208 patients were failing with NNRTI + zidovudine + lamivudine and 92 with NNRTI
+ non-TA. No significant differences were observed between the non-TA group and the ZDV
group regarding the time of virological failure [median (interquartile range): 12 (8–25) vs. 13
(9–32) months, respectively; P = 0.119] and viraemia [median (interquartile range): 4.0 (3.2–4.9)
vs. 4.0 (3.3–4.7) log10 copies/mL, respectively; P = 0.894]. Resistance to reverse transcriptase
inhibitors (RTIs) occurred at a significant lower frequency in the non-TA group than in the ZDV
group (54.3 vs. 75.5%, respectively; P = 0.001). This difference was mainly attributable to a
significantly lower prevalence of NNRTI resistance (54.3 vs. 74.0%, respectively; P = 0.002) and
of the nucleoside reverse transcriptase inhibitor (NRTI) mutation M184V (23.9 vs. 63.5%,
respectively; P < 0.001) in the non-TA group compared with the ZDV group. As expected, the
mutation K65R was found only in the non-TA group (18.5%; P < 0.001).
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Conclusions
At first-line regimen failure, a lower prevalence of RTI resistance was found in patients treated
with NNRTI + non-TA compared with those treated with NNRTI + zidovudine + lamivudine.
These results confirm that the choice of backbone may influence the prevalence of drug
resistance at virological failure.
Keywords: first-line regimen, genotypic resistance test, resistance to reverse transcriptase
inhibitors, virological failure
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Introduction
Highly active antiretroviral therapy (HAART) has resulted
in a reduction in morbidity and mortality among those
with HIV infection since its introduction into clinical use
[1]. Moreover, use of effective HAART is thought to limit
the transmission of HIV, and, as a consequence, of drug-
resistant viruses. Emergence of drug resistance has been
associated with poorer virological outcomes and increased
mortality in patients who receive first-line HAART [2,3].
For this reason, genotypic resistance testing (GRT) has
become an important component in the management of HIV
infection and is now recommended for both antiretroviral-
naïve and drug-experienced patients [4–6].
Currently, regimens containing two nucleos(t)ide reverse
transcriptase inhibitors (NRTIs) plus a nonnucleos(t)ide
reverse transcriptase inhibitor (NNRTI) as the third agent
are among the options strongly recommended by guide-
lines for first-line therapy [4–7]. In Western countries,
the NRTIs generally recommended as a component of first-
line regimens are lamivudine (3TC) or emtricitabine (FTC)
together with tenofovir (TDF), abacavir (ABC), zidovudine
(ZDV) or didanosine (ddI) [4–6], with the choice of NRTI
based on individual patient characteristics. The World
Health Organization (WHO) currently recommends starting
antiretroviral combination regimens with an NNRTI such
as nevirapine (NVP) or efavirenz (EFV), in combination
with 3TC or FTC and either ZDV [a thymidine analogue
(TA) inhibitor] or TDF (a non-TA) [7]. It is well recognized
that failure of a first-line regimen that includes two drugs
with low genetic barriers to resistance, such as EFV/NVP
and 3TC or FTC, is associated with an increased risk of
accumulation of resistance mutations [8–11]. This can,
in turn, limit therapeutic drug options for second-line
regimens. However, the emergence of drug resistance after
failure of a first-line regimen containing an NNRTI with
3TC/FTC and either ZDV or a non-TA such as TDF or ABC
has not been well characterized. The possibility should
be considered that the selection of resistance under ZDV
pressure may be intrinsically different from that under
non-TA pressure as a result of different genetic barriers
to resistance to these drugs [12], differences in penetra-
tion into target cells and/or different pharmacokinetics/
pharmacodynamics [13]. A recent study showed that
patients who experienced virological failure on regimens
containing TDF had lower rates of resistance emergence
than those who experienced virological failure on regimens
containing ZDV [14], probably because of the improved
tolerability, adherence and pharmacokinetics of TDF result-
ing from its once-daily dosage.
In this study we evaluated whether the emergence of drug
resistance in patients failing first-line regimens containing
an NNRTI administered with ZDV was comparable to that of
patients treated with a non-TA, such as TDF or ABC.
Methods
Study population and data collection
HIV-1-infected patients included in this study were selected
from two large Italian resistance databases [a database
collecting data for HIV-1-infected patients followed at
several clinical centres in Rome and the surrounding area,
and the multicentre Antiretroviral Resistance Cohort Analy-
sis (ARCA) database; https://www.hivarca.net/] and from
the UK Collaborative HIV Cohort (UK CHIC; http://www.
ukchic.org.uk/) with linked resistance data from the UK
HIV Drug Resistance Database (http://www.ctu.mrc.ac.uk/
hivrdb) (see Appendix S1). Eligible individuals were those
who experienced virological failure on a first-line regimen
that contained one NNRTI administered with either ZDV or
a non-TA. Virological failure was defined as a plasma HIV
RNA  400 HIV-1 RNA copies/ml for the first time after
at least 6 months of uninterrupted use of the NNRTI.
Patient information, including details of antiretroviral treat-
ment, viro-immunological values and the results of any
resistance tests performed at the time of virological failure,
was retrieved from the individual databases and merged
centrally.
Resistance analysis
The presence of mutations in the HIV-1 reverse tran-
scriptase (RT) was evaluated by comparing patients treated
with ZDV + 3TC vs. those treated with the non-TA + 3TC (or
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FTC). Drug-resistance mutations of interest were taken
from the latest International AIDS Society-USA report
[15] and the Stanford database (http://hivdb.stanford.edu).
Specifically, resistance to RT inhibitors (RTIs) was consid-
ered to exist if at least one NRTI mutation (M41L, A62V,
K65N/R, D67N, K70E/G/R, L74I/V, V75I, F77L, Y115F,
F116Y, Q151M, M184I/V, L210W, T215F/Y or K219E/Q) or
major EFV/NVP mutation (L100I, K101E/P, K103N/S,
V106A/M, V108I, Y181C/I/V, Y188C/H/L, G190A/E/S,
P225H, M230L or K238T) was present.
Statistical analysis
c2 tests (Pearson or Fisher’s exact test, where appropriate)
for categorical variables and the Mann–Whitney test for
continuous variables were used to compare the groups
receiving ZDV and a non-TA. The Benjamini–Hochberg
method was used to identify results that were statistically
significant in the presence of multiple-hypothesis testing
[16].
Logistic regression models were fitted to assess whether
the emergence of resistance to RTIs (at least one NRTI
mutation and/or at least one major EFV/NVP mutation),
NRTIs (at least one NRTI mutation) or NNRTIs (at least one
major EFV/NVP mutation) was associated with the type
of treatment received (ZDV vs. non-TA and NVP vs. EFV),
baseline viraemia, baseline CD4 cell count, and the time
elapsed from starting the first-line regimen to GRT at failure.
The statistical program used for analyses was SPSS for
Windows (version 17.0.1; SPSS, Chicago, IL).
Results
Patient characteristics and virological failure
Three hundred HIV-1-infected patients with failure of
a first-line NNRTI-containing regimen were included in
the analyses. Of these, 144 patients were Italian (74 were
followed in Rome and the surrounding area, and 70 were
from ARCA), and 156 were from UK CHIC. Of the 300
patients included in the analysis, 152 (50.7%) were treated
with EFV, while the remaining 148 (49.3%) were treated
with NVP. Two-hundred and eight patients had experi-
enced virological failure while on a regimen containing
ZDV + 3TC, while 92 had experienced virological failure on
a regimen containing a non-TA (TDF + 3TC: 36 patients;
TDF + FTC: 26 patients; ABC + 3TC: 30 patients). NVP was
mainly administered with ZDV + 3TC [ZDV group: 128
(61.5%); non-TA group: 20 (21.7%)], while EFV was mainly
administered with a non-TA [ZDV group: 80 (38.5%);
non-TA group: 72 (78.3%)] (P < 0.001). The characteristics
of patients according to treatment are summarized in
Table 1. In particular, as expected, patients treated with a
non-TA had started their first-line regimen more recently
than those treated with ZDV. In particular, the use of a
non-TA as part of the first-line regimen in this population
Table 1 Patients’ characteristics according to the treatment administered as the first-line regimen
Baseline characteristics
NRTI administered NNRTI administered
ZDV Non-TA P-value EFV NVP P-value
Number of patients 208 92 152 148
Male (%) 70.6 67.4 0.586 76.0 62.9 0.016
Age (years) [median (IQR)] 33 (26–41) 38 (29–44) 0.103 35 (29–43) 33 (26–41) 0.322
Risk factor (%)
Heterosexual 42.8 37.0 0.344 33.6 48.6 0.008
Homosexual 23.6 34.8 0.043 35.5 18.2 0.001
Sexual 1.4 4.3 0.124 2.6 2.0 0.729
Drug addiction 9.6 8.7 0.801 7.9 10.8 0.385
Other/unknown 22.6 15.2 0.143 20.4 20.4 0.437
BL viraemia (log copies/mL) [median (IQR)] 5.0 (4.4–5.3) 5.0 (4.1–5.6) 0.599 5.0 (4.2–5.4) 5.0 (4.3–5.4) 0.932
Subtype B* (%) 75.2 70.6 0.590 72.6 75.7 0.590
BL CD4 count (cells/mL) [median (IQR)] 224 (130–348) 150 (59–230) < 0.001 186 (86–253) 222 (104–325) 0.069
Year of therapy start [median (IQR)] 2002 (2000–2003) 2005 (2004–2007) < 0.001 2004 (2001–2006) 2002 (2000–2004) < 0.001
Time from starting first-line regimen to GRT at
failure (months) [median (IQR)]
18 (11–36) 15 (9–28) 0.011 18 (10–36) 15 (10–34) 0.613
Time of virological failure (months) [median (IQR)] 13 (9–32) 12 (8–25) 0.119 14 (9–34) 12 (8–25) 0.040
BL, baseline (the time of starting the first-line regimen); EFV, efavirenz; GRT, genotypic resistance test; IQR, interquartile range; NNRTI, nonnucleos(t)ide
reverse transcriptase inhibitor; NRTI, nucleos(t)ide reverse transcriptase inhibitor; non-TA, non-thymidine analogue; NVP, nevirapine; ZDV, zidovudine.
*Subtype information was available for about 50% of the population. Pearson c2 (for categorical variables) and the Mann–Whitney test (for continuous
variables) were used, where appropriate, to compare the following groups: (1) patients treated with a zidovudine (ZDV) regimen and those treated with a
non-thymidine analogue (non-TA) regimen (columns 2–4); (2) patients treated with an efavirenz (EFV) regimen and those treated with a nevirapine (NVP)
regimen (columns 5–7). In bold are indicated statistically significant differences (P < 0.05) in clinical and demographic parameters between the two groups.
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significantly increased over the years (from about 4%
before 2001 to 100% in 2009; P < 0.001 by c2 test for trend;
data not shown).
At the time of virological failure, no significant differ-
ences were observed between the ZDV and non-TA groups
regarding the time of virological failure [median (inter-
quartile range (IQR)) for the non-TA group: 12 (8–25)
months; for the ZDV group: 13 (9–32) months; P = 0.119]
or the viral load at failure [median (IQR) for the non-TA
group: 4.0 (3.2–4.9) log10 copies/mL; for the ZDV group: 4.0
(3.3–4.7) log10 copies/mL; P = 0.894]. However, a signifi-
cant difference was observed between the two groups in
terms of the duration of therapy at the time of the GRT
[median (IQR) for the non-TA group: 15 (9–28) months; for
the ZDV group: 19 (11–37) months; P = 0.011] (Table 1).
Of note, in the non-TA group no significant differences
in the patients’ characteristics were observed between
patients treated with TDF and those treated with ABC (data
not shown).
Genotypic resistance
In general, RTI resistance occurred at a lower frequency in
the non-TA group compared with the ZDV group (54.3 vs.
75.5%, respectively; P = 0.001) (Fig. 1). This difference was
mainly attributable to a significantly lower prevalence of
NNRTI resistance (54.3 vs. 74.0%, respectively; P = 0.002)
and of the 3TC/FTC mutation M184V (23.9 vs. 63.5%,
respectively; P < 0.001) in the non-TA group. In contrast,
M184I was found more frequently in the non-TA group (3.3
vs. 1.0% in the ZDV group; P = 0.12).
Of note, a smaller proportion of patients with at least
one TA mutation (M41L, D67N, K70R, L210W, T215F/Y or
K219E/Q) was observed in the non-TA group than in
the ZDV group (8.7 vs. 14.4%, respectively; P = 0.126). The
K103N mutation was the most common major EFV/NVP
mutation detected in both groups (non-TA group: 22.8%;
ZDV group: 38.9%; P = 0.010). Regarding ABC/TDF resist-
ance mutations, as expected, the mutations K65R and
Y115F were found only in the non-TA group (K65R: 18.5%;
P < 0.001; Y115F: 3.3%; P = 0.031), while the ABC resist-
ance mutation L74V was found almost exclusively in
the non-TA group (L74V: 4.3 vs. 0.5% in the ZDV group;
P = 0.032), in particular only in patients treated with ABC
(13.3 vs. 0% in TDF-treated patients; P = 0.010).
No other significant differences in the mutation preva-
lence were observed between patients treated with TDF and
those treated with ABC (data not shown).
Interesting findings were obtained for the NNRTI muta-
tions at RT positions 106, 181 and 190. In particular,
regarding the position 106, the V106M was the only EFV/
NVP mutation observed in both AZT-group (3.8%) and
non-TA-group (9.8%, P = 0.048). The mutation Y181I was
completely absent in the overall population, while the
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Fig. 1 Comparison of the prevalence of resistance mutations at first failure between the group of patients treated with a nonnucleos(t)ide reverse
transcriptase inhibitor (NNRTI) + zidovudine (ZDV) + lamivudine (3TC) and the group treated with an NNRTI + a non-thymidine analogue (non-TA)
+ 3TC/emtricitabine (FTC). Statistically significant differences in the mutation prevalence were assessed using Fisher’s exact test. All P-values in
the figure are for differences that were also significant after correction for multiple tests. The NNRTI mutation K101P and the nucleos(t)ide reverse
transcriptase inhibitor (NRTI) mutations K70G and L74I were completely absent in the analysed population. The following reverse transcriptase
inhibitor (RTI) mutations, with an overall prevalence of < 1.7% (n = 5 patients), are not shown in the figure: the NNRTI K103S, V106A and K238T and
the NRTIs K65N and K70E. TAM, thymidine analogue mutation.
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mutation Y181V was nearly absent in the non-TA group
(1.0 vs. 12.0% in ZDV group; P < 0.001). The mutation
G190A was found more frequently in the ZDV group (16.8
vs. 1.1% in the non-TA group; P < 0.001), while G190E was
found more frequently in the non-TA group (4.3 vs. 0.5%
in the ZDV group; P = 0.032).
Results from the multivariable logistic regression (after
adjusting for the type of treatment, baseline viraemia,
baseline CD4 cell count and the time elapsed from starting
the first-line regimen to GRT at failure) confirmed that RTI
resistance was more common in patients failing regimens
containing ZDV than in those failing regimens containing
a non-TA [adjusted odds ratio (AOR) 2.12; 95% confidence
interval (CI) 1.03–4.34; P = 0.039] and more common in
those failing a regimen containing NVP than in those
failing a regimen containing EFV (AOR 2.19; 95% CI 1.11–
4.33; P = 0.002). As expected, ZDV use was an independent
predictor of NRTI resistance (AOR 2.62; 95% CI 1.34–5.14;
P = 0.01), while NVP use was associated with NNRTI resist-
ance (AOR 2.28; 95% CI 1.15–4.39; P = 0.017) (Table 2).
The occurrence of both NRTI and NNRTI resistance was
also associated with higher baseline viraemia. Moreover, a
longer time from starting the treatment to GRT at failure
was associated with a reduced risk of RTI resistance, in
particular NNRTI resistance. No effect of subtype on the
occurrence of resistance was found in the subgroup of
patients for whom this variable was available (data not
shown).
Discussion
Analysing a cohort of patients failing a first-line NNRTI-
containing regimen, treatment with regimens that included
a non-TA (with 3TC/FTC) was associated with a reduced
risk of occurrence of drug resistance at the time of failure
compared with treatment with ZDV. This difference was
mainly attributable to a significantly lower prevalence
of NNRTI resistance and of the NRTI mutation M184V in
the non-TA group. To our knowledge, few data are avail-
able for the comparison of the emergence of resistance
after ZDV and non-TA failure [14]. This information is
important for clinicians and patients when choosing a
new therapy after first-line regimen failure, particularly in
resource-limited settings, where drug choices for second-
line regimens are limited and GRTs at failure are not
always available.
As expected, we found that the ABC/TDF-associated
mutation K65R was present exclusively in patients failing
regimens that included a non-TA, and the ABC mutation
L74V was exclusively present in ABC-treated patients,
while a higher proportion of TA mutations was found in
patients failing regimens that contained ZDV.
It is noteworthy that our resistance results are very
similar to those found in a study conducted in the Swiss
HIV Cohort, where 45 NNRTI failures were analysed (preva-
lences of K65R, K103N + Y181C, M184IV and at least one
TA mutation were 8, 39, 58 and 13%, respectively) [17]. The
overall prevalence of RTI resistance observed in our study
(69.3%) is also similar to that observed in a meta-analysis
of clinical trials comparing several regimens with NNRTI +
different backbones, performed by Gupta et al. (65.7%),
with a similar prevalence of K65R (5.7% in our study vs.
5.3% in Gupta et al.) [10]. However, the prevalence of other
mutations in our study was slightly higher compared with
that found in Gupta et al.’s meta-analysis. Indeed, in our
study the prevalences of NNRTI resistance, M184IV, and at
least one TA mutation were 68.0, 52.7 and 13.3%, respec-
tively, compared with 53.0, 35.3 and 1.5%, respectively, in
Gupta et al.’s study [10]. The lower prevalence of resistance
found in clinical trials may be a consequence of the fact
Table 2 Multivariable logistic regression models of factors predictive of the occurrence of drug resistance at failure of a first-line regimen
containing a nonnucleos(t)ide reverse transcriptase inhibitor (NNRTI) + zidovudine (ZDV) + lamivudine (3TC) or an NNRTI + a non-thymidine
analogue (non-TA) + 3TC/emtricitabine (FTC)
Factor
RTI resistance NRTI resistance NNRTI resistance
Odds ratio (95% CI) P-value Odds ratio (95% CI) P-value Odds ratio (95% CI) P-value
ZDV vs. non-TA 2.12 (1.03–4.34) 0.039 2.92 (1.46–5.84) 0.002 2.02 (0.98–4.14) 0.055
NVP vs. EFV 2.15 (1.08–4.28) 0.029 1.71 (0.90–3.21) 0.099 2.23 (1.12–4.45) 0.023
Baseline viraemia (per 1 log10 copies/mL increase) 1.39 (1.00–1.91) 0.046 1.49 (1.07–2.06) 0.017 1.45 (1.04–2.00) 0.025
Baseline CD4 count (per 50 cells/mL increase) 0.95 (0.89–1.02) 0.143 0.98 (0.92–1.05) 0.625 0.93 (0.87–1.00) 0.064
Time from starting first-line regimen to GRT at
failure (per 6 months more)
0.90 (0.82–0.98) 0.018 0.93 (0.86–1.02) 0.127 0.89 (0.82–0.98) 0.015
Three logistic regression models were built to evaluate factors independently associated with reverse transcriptase inhibitor (RTI), nucleos(t)ide reverse
transcriptase inhibitor (NRTI) or nonnucleos(t)ide reverse transcriptase inhibitor (NNRTI) resistance. Factors statistically significant in multivariable analyses
(P < 0.05) are indicated in bold.
CI, confidence interval; EFV, efavirenz; GRT, genotypic resistance testing; NRTI, nucleos(-t)ide reverse transcriptase inhibitor; NVP, nevirapine; RTI, reverse
transcriptase inhibitor.
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that studies of this type often do not adequately reflect the
‘real life’ of clinical practice. For instance, very frequently
in clinical trials, patients with specific characteristics are
excluded, such as those infected with a resistant virus or
patients with unstable lifestyles (e.g. injecting drug users),
which may have a behavioural effect that cannot be
adequately controlled for (e.g. nonadherence). Moreover,
our study is a retrospective study, and GRT was not always
immediately performed at virological failure or at the same
time for all the patients (as is generally the case in clinical
trials).
Multivariable analysis confirmed the association be-
tween an increased likelihood of RTI resistance and the use
of ZDV, with ZDV use being an independent predictor
of NRTI resistance. Moreover, multivariable analysis also
highlighted the greater prevalence of NNRTI resistance in
individuals with failure of regimens containing NVP. Both
NRTI and NNRTI resistance was associated with higher
baseline viraemia. We did not find an effect of subtype on
the prevalence of RTI resistance, although this information
was only available in around 50% of patients, of whom
around 70% were infected with subtype B, and thus these
analyses may have been under-powered. Thus, further
studies are required to better elucidate the role of subtype
in the emergence of resistance after first-line failure. Of
note, while our high prevalence of subtype B is consistent
with other studies which have reported a very high pre-
valence of B subtype in Western and Central Europe
[18], most HIV-1 infections world-wide, particularly in
resource-limited settings, are caused by other non-B sub-
types [18,19]. Our study has other limitations. An impor-
tant limitation of our analysis is the lack of information
regarding patients’ adherence to antiretroviral therapy, a
crucial factor in the achievement and maintenance of viro-
logical success. Another limitation is the lack of primary
resistance information; we could not exclude the possibil-
ity that some of the resistance mutations found at failure
may already have been present at baseline, prior to treat-
ment. For example, this was probably the case for the
eight patients harbouring a virus with at least one TA
mutation (T215 revertants, two patients; D67N, three
patients; T1215F, one patient; M41L, one patient; M41L +
D67N + L210W + T215F, one patient) and treated with a
non-TA, as TA mutations are generally not selected during
the use of non-TA-containing regimens. Moreover, as
patients were selected with no randomization, we cannot
exclude the possibility of unmeasured confounding. The
retrospective design did not permit a detailed description
of the emergence of mutations over time, as the GRT was
performed at varying times after virological failure. This
may have led to the inclusion of patients with different
mutation patterns as a result of different durations of
selective pressure exerted by antiretroviral drugs on virae-
mic individuals. However, when the time from starting the
first-line regimen to GRT at failure was included among the
covariates in the multivariable analysis, ZDV use (as well
NVP use) still remained independently associated with RTI
resistance development. Moreover, the number of patients
treated with non-TAs was small in comparison to those
treated with ZDV.
Nevertheless, our findings strongly suggest that the use
of a non-TA in the first-line regimen reduces the probabil-
ity of emergence of RTI resistance during failure. In con-
clusion, the results obtained in this study confirm that the
choice of backbone may influence the prevalence of drug
resistance at virological failure.
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